Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

IGF-1 DES peptide icon, one bubble per amino acidIGF-1 DES67 residuesTLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSAEach bubble = one amino acid. Size = residue mass. Color = chemical class.

IGF-1 DES

Beginner tier: 50 mcg, training days only (4-5x/week) · 4w on / 4w off · community consensus

~20-30 minutes half-life·Injection

Also known as: des(1-3)IGF-1, des-IGF-1, IGF-1 DES(1-3)

Ten times the potency of native IGF-1, cleared from circulation in under 30 minutes. IGF-1 DES (des(1-3) Insulin-like Growth Factor-1) is a 67-amino-acid truncated analog that bypasses all six IGF binding proteins. That bypass is the entire point. Without binding protein sequestration, every microgram reaches the receptor in free form. The trade-off is a half-life so short it demands intramuscular injection within minutes of finishing a set. Bodybuilders and advanced peptide users prize it for one thing no other compound replicates: site-specific muscle growth in the exact muscle group just trained.

What Is IGF-1 DES?

Sixty-seven amino acids. Three fewer than native IGF-1, and those three missing residues change everything. IGF-1 DES, also called des(1-3)IGF-1, drops the N-terminal tripeptide Gly-Pro-Glu that native IGF-1 uses to latch onto IGF binding proteins. The result: zero sequestration. Where native IGF-1 circulates 95 to 98 percent bound and biologically silent, the DES variant stays 100 percent free and active. Francis and colleagues reported the roughly 10-fold potency increase in 1988 (PMID 3390164 (opens in a new tab)). The same year, Cascieri and colleagues showed that IGF-1 mutants unable to bind IGFBPs cleared from rat serum in about 27 minutes, versus 100 minutes for native IGF-1 [1]. Ballard's group later mapped the full structural and binding profile [2].

Once it hits the IGF-1 receptor, the downstream signaling splits two ways. PI3K/Akt/mTOR drives protein synthesis. MAPK/ERK drives satellite cell proliferation, the pathway behind true muscle hyperplasia rather than just making existing fibers bigger. That satellite cell activation is what separates DES from conventional anabolics in the community conversation.

Practical use centers on one protocol: intramuscular injection into the target muscle within 10 to 15 minutes of finishing training. The short half-life means systemic exposure stays low while local receptor saturation stays high. Community reports across r/Peptides and r/steroids describe measurable localized size increases by weeks 3 to 4, with 50 to 100 mcg per muscle group being the most common dose range. No human clinical trials exist for this specific application. All efficacy data for site-specific hypertrophy comes from animal models and community experience.

How IGF-1 DES Works

The first three amino acids of native IGF-1 (Gly-Pro-Glu) form the primary recognition site for all six IGF binding proteins. Remove them and the molecule can no longer be captured. That single structural change is why IGF-1 DES reaches the receptor at full concentration while native IGF-1 circulates mostly in a bound, inactive state.

Receptor binding triggers autophosphorylation of the IGF-1 receptor (IGF-1R), which recruits IRS-1 (insulin receptor substrate-1). From there, signaling branches. The PI3K/Akt/mTOR arm phosphorylates p70S6K and 4E-BP1 to increase translation of muscle-specific mRNAs; this is direct protein synthesis stimulation. The MAPK/ERK arm activates satellite cell proliferation, the process behind muscle hyperplasia. New fiber formation as well as bigger existing fibers.

Because the half-life sits around 20 to 30 minutes, the anabolic signal is intense but brief. Tissue exposed to the injection gets saturated. Distant organs and tissues see minimal IGF-1R activation. That pharmacokinetic profile is why intramuscular delivery post-workout is standard; subcutaneous or systemic dosing wastes the compound to plasma clearance before it can concentrate at any target site.

IGF-1 DES Benefits

  • IGF-1 DES benefits center on localized anabolic signaling and satellite cell activation in targeted muscle tissue.
  • Site-specific muscle growth when injected intramuscularly post-workout. No other peptide replicates this localized effect at comparable potency.
  • Roughly 10x more potent than native IGF-1. Francis et al. confirmed this in rat muscle cell (L6 myoblast) assays (PMID 3390164 (opens in a new tab)).
  • Promotes true muscle hyperplasia through MAPK/ERK-driven satellite cell proliferation. Gains from new fiber formation may be more durable than hypertrophy alone.
  • Short half-life (approximately 25 minutes) limits systemic IGF-1 elevation. Off-target growth stimulation stays minimal compared to longer-acting variants like IGF-1 LR3.
  • Community users consistently report measurable localized size increases in lagging body parts by weeks 3 to 4 on the standard 50 to 100 mcg protocol.
  • Injury recovery stacks pairing DES with BPC-157 combine local IGF-1R activation with angiogenesis to accelerate tissue repair in the injected region.

IGF-1 DES: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Moderate
Based on 11 key studies·Research only

Well-established pharmacology: IGFBP non-binding confirmed, ~10x potency vs native IGF-1 confirmed [2], half-life ~27 min shown for other IGFBP non-binding IGF-I mutants in rats [1].

Dosing studied: 20–150 mcg IM per muscle group; animal studies do not translate to human dose recommendations
Read the evidence (key study, limitations)

Zero human clinical trials for site-specific muscle hypertrophy. Evidence base is preclinical only.

Key Study

Francis GL et al. 1988: des(1-3)IGF-I about 10x more potent than IGF-I in L6 myoblasts (PMID 3390164); Cascieri MA et al. 1988: IGFBP non-binding IGF-I mutants had a ~27 min serum half-life in rats vs 100 min for IGF-I (PMID 2454805); Ballard FJ et al. 1996: des(1-3)IGF-I structure and binding properties (PMID 8930132)

Limitations

No human RCTs or PK studies. No formal dose-response data in humans. All in vivo data from rodent models (gut resection, growth studies). No safety data beyond acute animal toxicology.

Community Experience
Moderate
3.5/5
Based on moderate: discussed in r/Peptides and r/steroids

Valued specifically for site-specific IM dosing post-workout.

Community dosing: 40–100 mcg IM per muscle group post-workout; bilateral splits common (e.g., 60 mcg left + 60 mcg right)
Read the reports (what users report 4, common issues 4)

Considered an advanced tool for lagging body parts. Enthusiasm tempered by hypoglycemia risk and product quality concerns.

What users report (4)
  • Site-specific muscle fullness and pump within first week
  • Measurable localized hypertrophy in lagging muscle groups by weeks 3–4
  • Short half-life limits systemic exposure compared to IGF-1 LR3
  • Unique site-specificity not replicable with any other peptide
Common issues (4)
  • Hypoglycemia: most common acute complaint, especially in users who skip post-injection carbs
  • High cost relative to short cycle length; small vials burn through quickly
  • Product quality inconsistency: purity varies; COA from Janoshik or Colmaric strongly recommended
  • Strict timing requirement (IM, post-workout only) reduces flexibility vs other IGF variants
Partially Aligned

Scientific mechanism (IGFBP bypass → local receptor saturation → MAPK/ERK-driven hyperplasia) is well-established and explains the community use case. However, human clinical data is absent: site-specific anabolic efficacy in healthy athletes is inferred, not proven. Community dose ranges (40–120 mcg IM) are extrapolated from animal data with no formal PK bridge.

IGF-1 DES Dosage Guide

CommunityCommunity dosing consensus from peptide research communities
LevelDose / InjectionFrequency
Beginner50 mcg
Training days only (4-5x/week)Track
Moderate80 mcg
Training days only (4-5x/week)Track
Aggressive120 mcg
Training days only (4-5x/week)Track
Note:

Reconstitution math for the two common vial sizes. For a 0.1 mg (100 mcg) vial: add 1 mL bacteriostatic water. Concentration becomes 100 mcg/mL. A 50 mcg dose is 50 units on a U-100 insulin syringe. For a 1 mg vial: add 2 mL bacteriostatic water. Concentration becomes 500 mcg/mL. A 50 mcg dose is 10 units; 80 mcg is 16 units; 100 mcg is 20 units on a U-100 syringe.

Timing is everything with DES. You have a 10-to-15-minute window after finishing the target muscle group to get the injection done. Prep your syringe before your last working set so you're ready. The ultra-short half-life means delays past 15 minutes post-workout significantly reduce local receptor exposure.

Product quality is a real concern. The research-chemical market for DES has documented purity inconsistencies. An independent Certificate of Analysis (Janoshik or Colmaric, for example) is the only outside check on what a vial contains. Start with a low test dose (20 to 30 mcg) to assess your blood glucose response before running a full protocol.

Cycling Protocol

On Period
4 weeks
Off Period
4 weeks

Short cycles of 4-6 weeks are standard due to potential IGF-1R desensitization with prolonged use. Some protocols use only on training days (3-5 days per week) to extend cycle duration while minimizing total exposure. Allow a full 4-week off period between cycles to restore receptor sensitivity.

Calculate your IGF-1 DES dose
Free dosage calculator with syringe visualization

Or use the universal Peptide Calculator for any peptide.

IGF-1 DES Protocols by Goal

advancedCommunity4–6 weeks on, 4 weeks off minimum
Dose assessment
Wk 1–2
50 mcg per muscle group (bilateral split: 25 mcg each side) · Training days only (4–5x/week) · Intramuscular: into the trained muscle group
Optimization
Wk 3–6
80–100 mcg per muscle group (bilateral split: 40–50 mcg each side) · Training days only · Intramuscular

Expected: Measurable localized size increase in injected muscle groups by week 4. Gains in muscle density and fiber count (hyperplasia) should be more durable than hypertrophy alone.

Monitor: Check fasting and post-injection blood glucose during week 1. If symptomatic hypoglycemia occurs, reduce dose to 30–40 mcg and optimize carbohydrate protocol before re-escalating.

How to Use IGF-1 DES

  1. 1
    Step 1

    Reconstitute lyophilized powder by adding bacteriostatic water to the vial. For a 1 mg vial, use 2 mL. Aim the stream down the glass wall, not directly onto the powder. Swirl gently until dissolved.

  2. 2
    Draw your dose with a 29 to 31 gauge insulin syringe

    For 50 mcg at 500 mcg/mL concentration, draw to the 10 unit mark. For 80 mcg, draw to 16 units. For 100 mcg, draw to 20 units.

  3. 3
    Step 3

    Inject intramuscularly into the muscle group you just finished training. Do this within 10 to 15 minutes of completing your last set. For bilateral muscles (quads, biceps, delts), split the dose between left and right sides.

  4. 4
    Step 4

    Immediately consume 20 to 50 grams of fast-acting carbohydrates. Dextrose powder, fruit juice, or glucose tablets all work. Do not skip this step.

  5. 5
    Step 5

    Monitor for hypoglycemia symptoms (shakiness, lightheadedness, mental fog) for 30 to 45 minutes post-injection. Keep additional carbs nearby during this window.

  6. 6
    Step 6

    Store the reconstituted vial upright in the refrigerator at 2 to 8 degrees Celsius. Use within 2 to 3 weeks. Discard if the solution turns cloudy or shows particulates.

  7. 7
    Rotate injection sites within each muscle group

    Do not hit the same spot more than 2 to 3 times per week. A standard cycle runs 4 to 6 weeks on, followed by 4 weeks off.

Alternative Routes

Intramuscular (IM)

Standard dose as listed; full local receptor exposure

The entire clinical rationale for DES is IM post-workout delivery. SubQ injection or systemic dosing eliminates the site-specific advantage and wastes compound to plasma clearance within 25–30 min.

Subcutaneous (SubQ)

Absorption occurs but local IM concentration in target muscle is not achieved; site-specific hyperplasia benefit is lost

May be used for injury recovery when the target tissue is superficial or SubQ injection can be placed close to the injury site. Some practitioners use SubQ for systemic IGF-1R effects at higher doses (100–150 mcg), though IGF-1 LR3 is better suited for systemic use.

Mixing your own vial? Use the IGF-1 DES reconstitution calculator for the exact BAC-water-to-mcg math on any vial size.

IGF-1 DES Stacking Protocols

Works With

Avoid

Insulin

Both insulin and IGF-1 DES drive glucose uptake via overlapping receptor pathways. Combination creates extreme and unpredictable hypoglycemia risk: cited as the single most dangerous combination in community harm-reduction literature.

Do not combine
IGF-1 LR3

Combining short-acting DES with long-acting LR3 creates layered IGF-1 receptor saturation and prolonged hypoglycemia risk. Community consensus: use one or the other, not both concurrently.

Do not combine
Sulfonylureas / oral hypoglycemics

Additive blood glucose lowering with IGF-1 DES increases hypoglycemia risk significantly.

GLP-1 agonists (semaglutide, tirzepatide)

Both affect glucose homeostasis. Combined use increases hypoglycemia risk and may amplify GI side effects.

Estimated Cost

Generic / Research
$75–$150 per 1 mg research-grade vial as of April 2026

Pricing updated 2026-04-09

IGF-1 DES Side Effects

Hypoglycemia is the primary acute risk and the side effect that demands the most attention. IGF-1 DES activates insulin-like glucose uptake through IGF-1R and insulin receptor cross-activation in skeletal muscle. Blood sugar can drop fast, especially at doses above 50 to 80 mcg systemic. Users who skip post-injection carbohydrates report lightheadedness, shakiness, and cognitive fog within 15 to 30 minutes of injection. Keep glucose tablets or fast-acting carbs (dextrose, fruit juice) within arm's reach. Always eat 20 to 50 grams of carbohydrates within 15 minutes of injecting. Never inject on an empty stomach. The risk is highest during weeks 1 and 2 while you're still calibrating your personal dose threshold.

Injection site reactions are common. Redness, swelling, and soreness at the intramuscular injection point appear frequently, particularly when the same site gets repeated hits. Do not inject into the same location more than 2 to 3 times per week. Chronic injection at one site raises a theoretical risk of localized tissue overgrowth.

Water retention and joint discomfort show up at higher doses. Some users report puffiness around injection sites and stiff joints during weeks 2 to 4 at doses above 80 mcg. These typically resolve when dose is reduced or the cycle ends.

Headaches and brain fog are reported but usually trace back to glucose fluctuations rather than a direct peptide effect. A finger-stick blood glucose reading will clarify the cause.

Cancer risk deserves direct acknowledgment. IGF-1R activation promotes cell proliferation. A Lancet meta-analysis of 12 prospective studies [3] found associations between raised circulating IGF-1 and increased cancer risk (prostate, colorectal, premenopausal breast). Anyone with active malignancy, a personal cancer history, or raised baseline IGF-1 should not use this compound. There is no ambiguity on this point.

No human clinical trials have evaluated IGF-1 DES safety at the doses used in the community. All safety data comes from animal models and user reports. Pregnancy and breastfeeding are absolute contraindications; no reproductive safety data exists.

When to stop: persistent symptomatic hypoglycemia despite carb loading, unusual localized swelling or tissue changes at injection sites, any new cancer diagnosis.

Common Issues & Solutions

Hypoglycemia within 30 min of injection → always pre-load 20–50g fast carbs; reduce dose to 30–40 mcg until response is established

No local pump or growth response → confirm IM injection (not SubQ), verify injection occurs within 10–15 min post-training, confirm vial purity with COA

Injection site redness or swelling that persists >48h → rotate sites; do not inject same location more than 2–3x per week

Headache or brain fog post-injection → typically blood glucose related; increase carbohydrate intake and check glucose with finger-stick meter

Diminishing response after week 4 → expected IGF-1R desensitization; proceed to 4-week off period before resuming

Ask AI about this page

Ask AI for a second opinion on IGF-1 DES dosing and side effects

Contraindications

  • Active or history of any malignancy: IGF-1R activation may accelerate tumor cell proliferation
  • Pregnancy or breastfeeding: no safety data available; stimulates cell growth pathways
  • Type 1 diabetes or poorly controlled type 2 diabetes: high risk of severe hypoglycemia
  • Individuals under 18 or with open growth plates: may cause disproportionate skeletal growth
  • Known hypersensitivity to IGF-1 or related growth factor peptides
  • Active acromegaly or elevated baseline IGF-1 levels
  • Diabetic retinopathy: IGF-1 may worsen retinal neovascularization

Drug Interactions

  • Insulin: significantly increased hypoglycemia risk; concurrent use requires intensive glucose monitoring and dose reduction
  • Sulfonylureas and other oral hypoglycemic agents: additive blood sugar lowering; monitor glucose closely
  • Growth hormone (HGH): combined IGF-1 axis stimulation; amplifies both anabolic effects and side effects including water retention and glucose dysregulation
  • IGF-1 LR3: combining short-acting and long-acting IGF-1 analogs may cause excessive receptor stimulation and prolonged hypoglycemia
  • GLP-1 receptor agonists (semaglutide, tirzepatide): both affect glucose homeostasis; increased hypoglycemia risk
  • Corticosteroids: may blunt IGF-1 anabolic effects through catabolic opposition and impaired protein synthesis
  • Both insulin and IGF-1 DES drive glucose uptake via overlapping receptor pathways. Combination creates extreme and unpredictable hypoglycemia risk: cited as the single most dangerous combination in community harm-reduction literature.
  • Combining short-acting DES with long-acting LR3 creates layered IGF-1 receptor saturation and prolonged hypoglycemia risk. Community consensus: use one or the other, not both concurrently.

Product Quality

Recommended Monitoring

TestWhenTarget
Blood glucose (finger-stick)Before injection and 30–45 min post-injection during week 1; ongoing if using doses >80 mcgPre-injection: >90 mg/dL; post-injection nadir: >70 mg/dL
Serum IGF-1Baseline before cycle; optional at cycle midpoint (week 3)Age-appropriate normal range; flag if >300 ng/mL at baseline
Fasting insulinBaseline recommended; especially if stacking with GH secretagogues or using >80 mcgNot listed
Local tissue inspectionEach injection sessionNot listed
Blood glucose (finger-stick)

IGF-1 DES drives skeletal muscle glucose uptake via IGF-1R/insulin receptor cross-activation; unmanaged hypoglycemia is the primary acute risk

Serum IGF-1

Elevated baseline IGF-1 (acromegaly, pre-existing GH axis dysfunction) substantially increases risk of adverse effects

Fasting insulin

IGF-1 DES has insulin-like activity; baseline metabolic status informs safe dose ceiling

Local tissue inspection

Chronic injection into the same site raises theoretical localized tissue overgrowth risk; rotate injection points and monitor for unusual swelling

IGF-1 DES Before and After

Days 1-3

Initial blood glucose fluctuations may occur. Mild pump sensation in injected muscles reported within the first session. Injection site soreness or redness possible. Establish post-workout timing and blood sugar management routine.

Weeks 1-2

Increased muscle fullness and pumps in injected muscle groups during and after training. Temporary water retention around injection sites. Appetite changes and mild hypoglycemia episodes if carb intake is not managed.

Weeks 3-4

Measurable improvements in injected muscle group size and recovery speed. Localized growth effects become visible in trained and injected areas. Peak response window for satellite cell activation and new fiber formation.

Weeks 5-6
extended cycle

Continued but potentially diminishing returns as IGF-1R sensitivity decreases. Cycle off after 4-6 weeks. Gains in muscle density and localized size should be retained with consistent training through the off period.

What to Expect

Days 1 to 3 (Calibration phase): Blood glucose is the main variable during these first sessions. IGF-1R activation drives acute glucose uptake in the injected muscle. Most users notice a localized pump effect during the workout itself. Mild lightheadedness or shakiness happens if the post-injection carb load is insufficient. Injection site soreness is common. The goal here is dialing in your carbohydrate timing and dose threshold, not chasing growth.

Weeks 1 to 2 (Pump and fullness onset): Satellite cell proliferation begins at the molecular level, though nothing structural has changed yet. What you will notice is increased fullness and vascularity in injected muscle groups during and between workouts. Water retention around injection sites is normal. Appetite changes are common. Joint stiffness or swelling can appear at doses above 80 mcg. Glucose fluctuations should be more predictable by now if your carb protocol is consistent.

Weeks 3 to 4 (Peak response window): This is when the community says the real results show up. Satellite cell activation and differentiation hit their maximum window based on animal model data. Measurable size increases in injected muscle groups become visible. Recovery speed improves noticeably. Some users report response beginning to plateau toward the end of week 4, which may signal early receptor desensitization.

Weeks 5 to 6 (Extended cycle and diminishing returns): IGF-1R downregulation is expected with prolonged agonist exposure. The response is clearly tapering. Most experienced users cycle off between weeks 4 and 6. Gains should retain well with continued training through the off period. The reduced efficacy itself is the signal to stop; pushing past it produces minimal benefit with ongoing risk.

Detailed Timeline: Science vs Community

Days 1–3
Science

IGF-1R activation drives acute glucose uptake in injected muscle tissue. Satellite cell signaling begins via MAPK/ERK pathway.

Community

Noticeable muscle pump in injected area during workout. Some report mild blood glucose dips (lightheadedness) if carb loading is insufficient.

Weeks 1–2
Science

Satellite cell proliferation begins. Local protein synthesis upregulated via PI3K/Akt/mTOR. No visible structural changes yet.

Community

Increased fullness and vascularity in injected muscle groups. Water retention around injection sites. Appetite changes common.

Weeks 3–4
Science

Maximum satellite cell activation and differentiation window. New myofiber formation (hyperplasia) hypothesized at this stage based on animal model data.

Community

Measurable size increases in injected muscle groups. Recovery speed notably improved. This is the window most users describe as the "real gains" phase.

Weeks 5–6
Science

IGF-1R downregulation expected with prolonged agonist exposure; receptor sensitivity diminishes.

Community

Response clearly diminishing. Most community members cycle off at week 4–6. Gains retain well with continued training during off period.

Pharmacokinetics

Half-Life
25min
Bioavailability
IM: ~100% bioactive (no IGFBP sequestration); SC: ~100% absorption but slower onset
Tmax
5-10 minutes (IM injection)
Data Confidence
moderate

Source: Estimated 20-30 min based on near-zero IGFBP affinity vs native IGF-1 (bound t½ ~12-15h, free t½ ~10 min); Cascieri et al. 1988 PMID 2454805, Ballard et al. 1996 PMID 8930132

Pharmacokinetics: Active Dose Over Time

t½ = ~20-30 minutes

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
67
Sequence
TLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 112603-35-7

Who Should Consider IGF-1 DES

  • Experienced peptide users seeking localized muscle growth in lagging body parts
  • Advanced athletes with prior IGF-1 or growth hormone experience
  • Individuals researching site-specific anabolic signaling and muscle hyperplasia
  • Adults recovering from localized muscle injuries (under medical supervision)
  • Researchers studying IGF-1R activation independent of IGFBP modulation

Related Peptides

What Changed for IGF-1 DES

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 202611 Citations

References

  1. [1]Serum half-life and biological activity of mutants of human insulin-like growth factor I which do not bind to serum binding proteins (Endocrinology, 1988) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I (Int J Biochem Cell Biol 1996) (opens in a new tab)PubMed (opens in a new tab)Review
  3. [3]IGF-I, IGFBP-3, and cancer risk: systematic review and meta-regression analysis (Lancet, 2004) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Stable at room temperature for up to 30 days; refrigerated at 2-8°C for up to 24 months
After Reconstitution
Refrigerate at 2-8°C, use within 2-3 weeks. Do not freeze.
Temperature
2-8°C (36-46°F) after reconstitution

Frequently Asked Questions

The ultra-short half-life (~20-30 min) is why. DES is cleared from circulation so quickly that injecting into a just-trained muscle maximizes local receptor exposure before the compound disappears. Post-exercise, that muscle also has upregulated IGF-1 receptors. A subcutaneous or systemic injection would mostly be wasted to plasma clearance.

Not at all. DES is shorter than native IGF-1 (67 vs 70 amino acids); missing the first 3 amino acids that allow binding protein attachment. LR3 is longer (83 amino acids) with modifications that reduce binding protein affinity differently. DES is ~10x more potent but clears in ~25 minutes. LR3 is ~3x more potent with a 20-30 hour functional half-life. Completely different use cases.

It's the most commonly reported acute risk. Always consume 20-50g fast-acting carbs (dextrose, fruit juice) within 10-15 minutes of injection. Never inject on an empty stomach. Keep glucose tablets on hand. The risk is highest during weeks 1-2 while you're finding your dose threshold. Above 50-80 mcg systemic, glucose drops become significant.

Hypertrophy is making existing muscle fibers bigger; the normal training response. Hyperplasia is creating entirely new muscle fibers through satellite cell activation. IGF-1 DES activates the MAPK/ERK pathway that drives satellite cell proliferation. The practical implication: gains from hyperplasia may be more durable because you have more fibers.

Yes, this is standard practice; inject bilaterally into the trained muscle group (e.g., 60 mcg left quad, 60 mcg right quad = 120 mcg total). Don't inject the same site more than 2-3x per week to avoid localized tissue overgrowth.